<p>加拿大不列颠哥伦比亚省温哥华 --（Newsfile Corp. -2026 年 5 月 19 日）- InMed Pharmaceuticals Inc. <strong>（NASDAQ: INM）</strong>（&#34; <strong>InMed</strong>&#34; 或 &#34; <strong>公司</strong>&#34;），是一家专注于开发针对高未满足医疗需求疾病的专有小分子药物候选者的制药公司，今天宣布已与 Armistice Capital Master Fund Ltd.（&#34;Armistice&#34;）签署了一项修订协议，涉及 Armistice 持有的某些未偿还优先投资选择权。</p>
<p>如之前所述，根据 2023 年 10 月 26 日向 Armistice 发行的某些优先投资选择权的条款（&#34;Armistice 优先投资选择权&#34;），公司向 Armistice 提供了认购和购买公司最多 278,761 股普通股的权利，普通股的行使价格为每股 16.60 美元，需进行调整（&#34;Armistice 行使价格&#34;）。</p>
<p>公司已与 Armistice 签署修订协议，将 Armistice 行使价格从 16.60 美元修订为 0.80 美元。Armistice 优先投资选择权是在根据 1933 年证券法第 4(a)(2) 条款及其下发布的 D 条款进行的私人配售中提供的。不能保证任何 Armistice 优先投资选择权会被行使。</p>
<p>有关更多信息，请参见公司向证券交易委员会提交的文件，包括公司不时向证券交易委员会提交的 8-K 表格的当前报告。</p>
<p><strong>关于 InMed</strong></p>
<p>InMed Pharmaceuticals 是一家专注于开发针对 CB1/CB2 受体的专有小分子药物候选者的制药公司。InMed 的管道包括三个独立的项目，针对阿尔茨海默病、眼科和皮肤科适应症。有关更多信息，请访问 www.inmedpharma.com。</p>
<p><strong>投资者联系：</strong></p>
<p>Colin Clancy</p>
<p>副总裁，投资者关系</p>
<p>及企业传播</p>
<p>电话：+1.604.416.0999</p>
<p>电子邮件：ir@inmedpharma.com</p>
<p><strong>关于前瞻性信息的警示说明：</strong></p>
<p>本新闻稿包含适用证券法意义上的&#34;前瞻性信息&#34;和&#34;前瞻性声明&#34;（统称为&#34;前瞻性信息&#34;）。前瞻性信息基于管理层当前的期望和信念，并受到多种风险和不确定性的影响，这些因素可能导致实际结果与前瞻性声明中描述的结果有重大差异。在不限制前述内容的情况下，本新闻稿中的前瞻性信息包括但不限于关于在到期前行使 Armistice 优先投资选择权的声明。</p>
<p>关于本新闻稿中包含的前瞻性信息，InMed 做出了许多假设，包括但不限于：及时获得所有必要的监管批准的能力，或根本无法获得；以及持续的经济和市场稳定。虽然 InMed 认为这些假设是合理的，但这些假设本质上受到重大商业、经济、竞争、市场和社会不确定性和偶然事件的影响。此外，还有已知和未知的风险因素可能导致 InMed 的实际结果、表现或成就与本文件中所表达或暗示的任何未来结果、表现或成就有重大不同。有关 InMed 独立业务面临的风险和不确定性的完整讨论已在 InMed 的 10-K 表格年度报告、10-Q 表格季度报告及其他向证券交易委员会提交的文件中披露，网址为 www.sec.gov。</p>
<p>本文件中的所有前瞻性信息均受到本警示声明的完全限制，InMed 不承担修订或更新任何此类前瞻性信息的义务，或公开宣布对本文件中包含的任何前瞻性信息的任何修订结果，以反映未来的结果、事件或发展，法律要求的情况除外。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9540/297903_701bba8d847f1b7b_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9540/297903_701bba8d847f1b7b_logo.jpg"/></p>
<p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/297903</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/297903/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/297903/375"/></p>

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

<p>InMed Pharmaceuticals Inc. 已修订与 Armistice Capital Master Fund Ltd. 的协议，涉及优先投资选项。购买普通股的行使价格已从 16.60 美元降低至 0.80 美元。这些选项是根据证券法进行的私募配售的一部分。无法保证这些选项会被行使</p>

<p>Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. <strong>(NASDAQ: INM)</strong>(&#34; <strong>InMed</strong>&#34; or the &#34; <strong>Company</strong>&#34;), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into an amending agreement with Armistice Capital Master Fund Ltd. (&#34;Armistice&#34;) in respect of certain outstanding preferred investment options held by Armistice.</p>
<div class="lb-trans"><p>加拿大不列颠哥伦比亚省温哥华 --（Newsfile Corp. -2026 年 5 月 19 日）- InMed Pharmaceuticals Inc. <strong>（NASDAQ: INM）</strong>（&#34; <strong>InMed</strong>&#34; 或 &#34; <strong>公司</strong>&#34;），是一家专注于开发针对高未满足医疗需求疾病的专有小分子药物候选者的制药公司，今天宣布已与 Armistice Capital Master Fund Ltd.（&#34;Armistice&#34;）签署了一项修订协议，涉及 Armistice 持有的某些未偿还优先投资选择权。</p>
</div><p>As previously reported, pursuant to the terms of certain preferred investment options dated October 26, 2023 issued to Armistice (the &#34;Armistice Preferred Investment Options&#34;), the Company provided Armistice with the right to subscribe for and purchase from the Company up to 278,761 common shares in the capital of the Company at an exercise price per common share of $16.60, subject to adjustment (the &#34;Armistice Exercise Price&#34;).</p>
<div class="lb-trans"><p>如之前所述，根据 2023 年 10 月 26 日向 Armistice 发行的某些优先投资选择权的条款（&#34;Armistice 优先投资选择权&#34;），公司向 Armistice 提供了认购和购买公司最多 278,761 股普通股的权利，普通股的行使价格为每股 16.60 美元，需进行调整（&#34;Armistice 行使价格&#34;）。</p>
</div><p>The Company has entered into an amending agreement with Armistice in respect of the Armistice Preferred Investment Options to amend the Armistice Exercise Price from $16.60 to $0.80. The Armistice Preferred Investment Options were offered in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder. No assurance can be given that any of the Armistice Preferred Investment Options will be exercised.</p>
<div class="lb-trans"><p>公司已与 Armistice 签署修订协议，将 Armistice 行使价格从 16.60 美元修订为 0.80 美元。Armistice 优先投资选择权是在根据 1933 年证券法第 4(a)(2) 条款及其下发布的 D 条款进行的私人配售中提供的。不能保证任何 Armistice 优先投资选择权会被行使。</p>
</div><p>For further information, please see the Company's filings with the Securities and Exchange Commission, including the Company's Current Reports on Form 8-K filed with the Securities and Exchange Commission from time to time.</p>
<div class="lb-trans"><p>有关更多信息，请参见公司向证券交易委员会提交的文件，包括公司不时向证券交易委员会提交的 8-K 表格的当前报告。</p>
</div><p><strong>About InMed</strong></p>
<div class="lb-trans"><p><strong>关于 InMed</strong></p>
</div><p>InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.</p>
<div class="lb-trans"><p>InMed Pharmaceuticals 是一家专注于开发针对 CB1/CB2 受体的专有小分子药物候选者的制药公司。InMed 的管道包括三个独立的项目，针对阿尔茨海默病、眼科和皮肤科适应症。有关更多信息，请访问 www.inmedpharma.com。</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>Colin Clancy</p>
<div class="lb-trans"><p>Colin Clancy</p>
</div><p>Vice President, Investor Relations</p>
<div class="lb-trans"><p>副总裁，投资者关系</p>
</div><p>and Corporate Communications</p>
<div class="lb-trans"><p>及企业传播</p>
</div><p>T: +1.604.416.0999</p>
<div class="lb-trans"><p>电话：+1.604.416.0999</p>
</div><p>E: ir@inmedpharma.com</p>
<div class="lb-trans"><p>电子邮件：ir@inmedpharma.com</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Information:</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性信息的警示说明：</strong></p>
</div><p>This news release contains &#34;forward-looking information&#34; and &#34;forward-looking statements&#34; (collectively, &#34;forward-looking information&#34;) within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about the exercise of the Armistice Preferred Investment Options prior to their expiration.</p>
<div class="lb-trans"><p>本新闻稿包含适用证券法意义上的&#34;前瞻性信息&#34;和&#34;前瞻性声明&#34;（统称为&#34;前瞻性信息&#34;）。前瞻性信息基于管理层当前的期望和信念，并受到多种风险和不确定性的影响，这些因素可能导致实际结果与前瞻性声明中描述的结果有重大差异。在不限制前述内容的情况下，本新闻稿中的前瞻性信息包括但不限于关于在到期前行使 Armistice 优先投资选择权的声明。</p>
</div><p>With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, InMed's Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on www.sec.gov.</p>
<div class="lb-trans"><p>关于本新闻稿中包含的前瞻性信息，InMed 做出了许多假设，包括但不限于：及时获得所有必要的监管批准的能力，或根本无法获得；以及持续的经济和市场稳定。虽然 InMed 认为这些假设是合理的，但这些假设本质上受到重大商业、经济、竞争、市场和社会不确定性和偶然事件的影响。此外，还有已知和未知的风险因素可能导致 InMed 的实际结果、表现或成就与本文件中所表达或暗示的任何未来结果、表现或成就有重大不同。有关 InMed 独立业务面临的风险和不确定性的完整讨论已在 InMed 的 10-K 表格年度报告、10-Q 表格季度报告及其他向证券交易委员会提交的文件中披露，网址为 www.sec.gov。</p>
</div><p>All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.</p>
<div class="lb-trans"><p>本文件中的所有前瞻性信息均受到本警示声明的完全限制，InMed 不承担修订或更新任何此类前瞻性信息的义务，或公开宣布对本文件中包含的任何前瞻性信息的任何修订结果，以反映未来的结果、事件或发展，法律要求的情况除外。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9540/297903_701bba8d847f1b7b_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/9540/297903_701bba8d847f1b7b_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297903</p>
<div class="lb-trans"><p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/297903</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/297903/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/297903/375"/></p>

InMed Pharmaceuticals 修改了优先投资选项 | INM 股票新闻